TEM:NASDAQTempus AI, Inc. Analysis
Data as of 2026-07-30 - not real-time
$41.55
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Tempus AI, Inc. is trading just above its recent support of $40.77, with the current price of $41.55 reflecting a modest upside of roughly 2% from that floor. Technicals are mixed: the 20‑day SMA sits above the 50‑day SMA, yet the 200‑day SMA remains well above price, and a bearish MACD histogram (‑1.70) together with an RSI of 31.6 suggests the stock is oversold and vulnerable to further downside. Volatility is extreme at 69% over the past 30 days and beta exceeds 2.4, indicating high sensitivity to market swings. On the fundamentals side, revenue grew 36% YoY to $1.36 B, but margins are negative (operating margin ‑24%, profit margin ‑22%) and the balance sheet is strained with a debt‑to‑equity ratio over 300%, leading to a forward PE of ‑525 and a price‑to‑book of 17.9.
The recent definitive agreement to acquire Personalis expands TEM’s MRD capabilities, potentially unlocking higher‑margin data services, while institutional backing from BlackRock (5.1%) and ARK (5.5%) underscores confidence in the AI‑driven growth narrative. Analyst consensus remains a “Buy” with a median target near $64.5, implying a 55% upside, but the combination of high leverage, negative cash flow and extreme market sentiment (Fear‑Greed Index at “Extreme Greed”) warrants caution.
The recent definitive agreement to acquire Personalis expands TEM’s MRD capabilities, potentially unlocking higher‑margin data services, while institutional backing from BlackRock (5.1%) and ARK (5.5%) underscores confidence in the AI‑driven growth narrative. Analyst consensus remains a “Buy” with a median target near $64.5, implying a 55% upside, but the combination of high leverage, negative cash flow and extreme market sentiment (Fear‑Greed Index at “Extreme Greed”) warrants caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price hovering just above technical support
- Bearish MACD and oversold RSI
- High short‑term volatility and beta
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Acquisition of Personalis expanding high‑margin services
- Strong institutional ownership and analyst buy consensus
- Revenue growth outpacing peers despite current losses
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic AI and data platform positioning in precision medicine
- Potential for improved profitability as data services scale
- Long‑term upside from market‑wide AI adoption in healthcare
Key Metrics & Analysis
Financial Health
Revenue Growth36.10%
Profit Margin-22.20%
P/E Ratio-524.8
ROE-81.58%
ROA-9.07%
Debt/Equity316.65
P/B Ratio17.9
Op. Cash Flow$-185743008
Free Cash Flow$-55760000
Industry P/E29.9
Technical Analysis
TrendNeutral
RSI31.6
Support$40.77
Resistance$63.11
MA 20$52.90
MA 50$51.05
MA 200$59.91
MACDBearish
VolumeIncreasing
Fear & Greed Index87.09
Valuation
Target Price$66.57
Upside/Downside60.22%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.47
Volatility69.30%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.